Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance
- 1 July 1996
- journal article
- research article
- Published by American Society for Microbiology in Journal of Bacteriology
- Vol. 178 (14) , 4060-4069
- https://doi.org/10.1128/jb.178.14.4060-4069.1996
Abstract
DNA topoisomerase IV mediates chromosome segregation and is a potential target for antibacterial agents including new antipneumococcal fluoroquinolones. We have used hybridization to a Staphylococcus aureus gyrB probe in concert with chromosome walking to isolate the Streptococcus pneumoniae parE-parC locus, lying downstream of a putative new insertion sequence and encoding 647-residue ParE and 823-residue ParC subunits of DNA topoisomerase IV. These proteins exhibited greatest homology respectively to the GrlB (ParE) and GrlA (ParC) subunits of S. aureus DNA topoisomerase IV. When combined, whole-cell extracts of Escherichia coli strains expressing S. pneumoniae ParC or ParE proteins reconstituted a salt-insensitive ATP-dependent decatenase activity characteristic of DNA topoisomerase IV. A second gyrB homolog isolated from S. pneumoniae encoded a 648-residue protein which we identified as GyrB through its close homology both to counterparts in S. aureus and Bacillus subtilis and to the product of the S. pneumoniae nov-1 gene that confers novobiocin resistance. gyrB was not closely linked to gyrA. To examine the role of DNA topoisomerase IV in fluoroquinolone action and resistance in S. pneumoniae, we isolated mutant strains stepwise selected for resistance to increasing concentrations of ciprofloxacin. We analysed four low-level resistant mutants and showed that Ser-79 of ParC, equivalent to resistance hotspots Ser-80 of GrlA and Ser-84 of GyrA in S. aureus, was in each case substituted with Tyr. These results suggest that DNA topoisomerase IV is an important target for fluoroquinolones in S. pneumoniae and establish this organism as a useful gram-positive system for resistance studies.Keywords
This publication has 36 references indexed in Scilit:
- Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1995
- The Role of New Quinolones in the Treatment of Respiratory Tract InfectionsDrugs, 1995
- In Vitro Activity of Fluoroquinolones against Gram-Positive BacteriaDrugs, 1995
- Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone‐resistant isolatesMolecular Microbiology, 1994
- Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalisAntimicrobial Agents and Chemotherapy, 1994
- Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolonesMolecular Microbiology, 1994
- The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replicationCell, 1992
- Inhibition by quinolones of DNA gyrase from Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1991
- New topoisomerase essential for chromosome segregation in E. coliCell, 1990
- A Sign Inversion Mechanism for Enzymatic Supercoiling of DNAScience, 1979